Phase 2Active, not recruiting
A Phase II Clinical Study on the Efficacy and Safety of HRS-1780 in Participants With Primary Aldosteronism
A Multicenter, Randomized, Double-blind, Parallel, Placebo-controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of HRS-1780 in Participants With Primary Aldosteronism
- Sponsor
- Shandong Suncadia Medicine Co., Ltd. (Industry)
- Enrolment
- 61 enrolled
- Conditions
- Primary Aldosteronism
- Interventions
- HRS-1780 Tablets; Placebo
- Ages
- adults, older adults
- Registry
- NCT07470983
Full record on ClinicalTrials.gov
From the registry
This study is a multicenter, randomized, double-blind, placebo-parallel-controlled phase II clinical trial to evaluate the efficacy and safety of HRS-1780 compared with placebo in participants with primary aldosteronism. The study plans to enroll 60 participants.
Primary outcomes
- Change from baseline in office systolic blood pressure (SBP);
History
Primary completion expected
Last registry update
Started
Registered